Références
- Brown WN. Alone in My Universe: Struggling with an Orphan Disease in an Unsympathetic World.: iUniverse, 2011: ISBN:978-1-4502-9592-5
- Gurel MH, Bruening PR, Rhodes C, et al. Patient perspectives on the impact of acromegaly: results from individual and group interviews. Patient Prefer Adherence 2014;8:53-62.
- Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis 2008;3:17.
- Melmed S. Acromegaly. New England Journal of Medicine 2006;355:2558-2573.
- Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary 1999;2:29-41.
- Katznelson L, Laws ER, Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:3933-51.
- Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992;21:597-614.
- Rowland NC, Aghi MK. Radiation treatment strategies for acromegaly. Neurosurg Focus 2010;29:E12.
- Miller A, Doll H, David J, et al. Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol 2008;158:587-93.
- Somatuline LA, SmPc.
- Octréotide, SmPc.
- Somavert®, SmPc.
- van der Lely AJ, et al. J Clin Endocrin Metab, 2012; 97(5): 1-9
- van der Lely AJ, et al. Lancet 2001 Nov 24; 358(9295): 1754-9.
- Sang Ouk C. et al., Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement. Endocrinol Metab (Seoul). 2019 Mar; 34(1): 53–62.
- Chanson P. et al., Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs. Neuroendocrinology 2016;103:50–58
- J. Van Esdonk M. et al., How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary. 2018; 21(3): 310–322
- Bromocriptine, SmPc
